Genscript Biotech Förvaltning

Förvaltning kriterier kontrolleras 2/4

Genscript Biotech VD är Sherry Shao, utsedd i Jul 2021, har en mandatperiod på 3.67 år. totala årliga ersättningen är $ 2.48M, bestående av 14.3% lön 85.7% bonusar, inklusive företagsaktier och optioner. äger direkt 0.033% av företagets aktier, värda HK$ 9.62M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 4 år respektive 4.3 år.

Viktig information

Sherry Shao

Verkställande direktör

US$2.5m

Total ersättning

VD-lön i procent	14.3%
Anställning som VD	3.7yrs
Ägande av VD	0.03%
Ledningens genomsnittliga anställningstid	4yrs
Styrelsens genomsnittliga mandatperiod	4.3yrs

Senaste uppdateringar av ledningen

Recent updates

Investors Still Aren't Entirely Convinced By Genscript Biotech Corporation's (HKG:1548) Revenues Despite 27% Price Jump

Feb 12

Genscript Biotech Corporation (HKG:1548) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jan 20

Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)

Nov 19

Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?

Oct 01

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Sep 16

After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar

Aug 02

Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch

Jun 05

A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)

May 10

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 13

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Mar 13

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 26

Is Genscript Biotech (HKG:1548) A Risky Investment?

Nov 21

Is Genscript Biotech (HKG:1548) A Risky Investment?

Aug 22

Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook

Apr 04

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Apr 03

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 02

Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate

Feb 07

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Dec 14

Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate

Nov 09

Analys av ersättningar till VD

Hur har Sherry Shao:s ersättning förändrats jämfört med Genscript Biotech:s resultat?
Datum	Total ersättning	Lön	Företagets resultat
Jun 30 2024	n/a	n/a	-US$177m
Mar 31 2024	n/a	n/a	-US$136m
Dec 31 2023	US$2m	US$353k	-US$95m

Ersättning vs marknad: Sherry s total kompensation ($USD 2.48M ) är över genomsnittet för företag av liknande storlek på Hong Kong marknaden ($USD 630.36K ).

Ersättning vs inkomst: Otillräcklig data för att jämföra Sherry s ersättning med företagets resultat.

VD OCH KONCERNCHEF

Sherry Shao (43 yo)

3.7yrs

Anställning

US$2,477,000

Kompensation

Ms. Weihui Shao, also known as Sherry, is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined t...

Ledningsgrupp

Namn	Position	Anställning	Kompensation	Ägarskap
Jiange Meng	Executive Chairman	9.6yrs	US$495.00k	0.015% HK$ 4.3m
Weihui Shao	CEO & COO	3.7yrs	US$2.48m	0.033% HK$ 9.6m
Ye Wang	Co-Founder	23.2yrs	US$659.00k	0.038% HK$ 10.8m
Luquan Wang	Co-Founder & Non-Executive Director	no data	inga uppgifter	0.030% HK$ 8.5m
Fangliang Zhang	Co-Founder & Executive Director	2.3yrs	US$531.00k	inga uppgifter
Li Zhu	Chief Strategy Officer & Executive Director	4.3yrs	US$320.00k	0.055% HK$ 15.7m
Shiniu Wei	Chief Financial Officer	4.3yrs	inga uppgifter	inga uppgifter
Kening Li	General Counsel & Chief Compliance Officer	no data	inga uppgifter	inga uppgifter
Raymond Miller	Head of Corporate Communications	no data	inga uppgifter	inga uppgifter
Aylin Bilgin	Chief Marketing Officer for GenScript Life Science Group	less than a year	inga uppgifter	inga uppgifter
Bhama Parimoo	Head of Global Diversity	no data	inga uppgifter	inga uppgifter
Ernest Lee	Head of Sustainability	no data	inga uppgifter	inga uppgifter

4.0yrs

Genomsnittlig anställningstid

56yo

Genomsnittlig ålder

Erfaren ledning: 1548 s ledningsgrupp anses vara erfaren ( 4 års genomsnittlig anställningstid).

Styrelseledamöter

Namn	Position	Anställning	Kompensation	Ägarskap
Jiange Meng	Executive Chairman	9.6yrs	US$495.00k	0.015% HK$ 4.3m
Ye Wang	Co-Founder	9.8yrs	US$659.00k	0.038% HK$ 10.8m
Luquan Wang	Co-Founder & Non-Executive Director	9.8yrs	inga uppgifter	0.030% HK$ 8.5m
Fangliang Zhang	Co-Founder & Executive Director	2.8yrs	US$531.00k	inga uppgifter
Li Zhu	Chief Strategy Officer & Executive Director	4.3yrs	US$320.00k	0.055% HK$ 15.7m
Carl June	Member of Advisory Board	1.2yrs	inga uppgifter	inga uppgifter
George Church	Member of Advisory Board	5.5yrs	inga uppgifter	inga uppgifter
David Liu	Member of Scientific Advisory Board	1yr	inga uppgifter	inga uppgifter
Zumian Dai	Independent Non-Executive Director	no data	US$46.00k	0.00065% HK$ 187.0k
Jiuan Pan	Independent Non-Executive Director	6.3yrs	US$46.00k	0.00021% HK$ 60.4k
Yiu Leung Cheung	Independent Non-Executive Director	less than a year	inga uppgifter	inga uppgifter
Chenyang Shi	Independent Non-Executive Director	less than a year	inga uppgifter	inga uppgifter

4.3yrs

Genomsnittlig anställningstid

56yo

Genomsnittlig ålder

Erfaren styrelse: 1548 s styrelse anses vara erfaren ( 4.3 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2025/03/09 01:46
Aktiekurs vid dagens slut	2025/03/07 00:00
Intäkter	2024/06/30
Årlig intjäning	2023/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Genscript Biotech Corporation bevakas av 19 analytiker. 11 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Linda Lu	BOCI Research Ltd.
Jin Zhang	China International Capital Corporation Limited
Yue-Kwong Lui	China Renaissance Securities

Genscript Biotech Förvaltning

Förvaltning kriterier kontrolleras 2/4

Viktig information

Senaste uppdateringar av ledningen

Genscript Biotech Corporation Announces Establishment of A Sub-Committee of the Risk Management and ESG Committee

Executive Chairman exercised options and sold HK$5.5m worth of stock

Executive Chairman recently sold HK$396k worth of stock

Co-Founder exercised options and sold HK$53m worth of stock

Co-Founder exercised options and sold HK$43m worth of stock

Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group

Recent updates

Genscript Biotech Corporation to Report Fiscal Year 2024 Results on Mar 11, 2025

Investors Still Aren't Entirely Convinced By Genscript Biotech Corporation's (HKG:1548) Revenues Despite 27% Price Jump

Genscript Biotech Corporation Announces Establishment of A Sub-Committee of the Risk Management and ESG Committee

Genscript Biotech Corporation (HKG:1548) Shares Could Be 49% Below Their Intrinsic Value Estimate

Executive Chairman exercised options and sold HK$5.5m worth of stock

Executive Chairman recently sold HK$396k worth of stock

Co-Founder exercised options and sold HK$53m worth of stock

Co-Founder exercised options and sold HK$43m worth of stock

Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)

Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group

Board Member recently sold HK$901k worth of stock

Now 22% overvalued after recent price rise

Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?

Genscript Biotech Corporation Announces Late-Breaking Long-Term Overall Survival Data from Cartitude-4 Study in Multiple Myeloma

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Genscript Biotech Corporation Announces Board Appointments

Consensus EPS estimates fall by 46%

First half 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar

Genscript Biotech Corporation to Report First Half, 2024 Results on Aug 09, 2024

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market

Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)

Full year 2023 earnings: EPS exceeds analyst expectations

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Consensus estimates of losses per share improve by 12%

Consensus EPS estimates upgraded to US$0.054 loss, revenue downgraded

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

New minor risk - Profitability

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Executive Chairman recently sold HK$610k worth of stock

Executive Chairman exercised options and sold HK$4.5m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?

Independent Non-Executive Director exercised options and sold HK$1.6m worth of stock

Non-Executive Director exercised options and sold HK$2.4m worth of stock

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

Is Genscript Biotech (HKG:1548) A Risky Investment?

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold HK$1.4m worth of stock

Consensus revenue estimates fall by 19%

Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Is Genscript Biotech (HKG:1548) A Risky Investment?

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate

Now 24% undervalued

Now 20% undervalued

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Less than half of directors are independent

Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate

Is Genscript Biotech (HKG:1548) Using Debt Sensibly?

Consensus forecasts updated

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022